(Mountain Standard Time)
6:00 PM - 8:00 PM
MASH-TAG 2025 Reception
Degas/Renoir Ballroom, The Chateaux
6:45 AM - 7:30 AM
Breakfast
7:30 AM - 7:35 AM
Opening Remarks
Presenter: Vlad Ratziu, MD, PhD
7:35 AM - 8:05 AM
The Year 2024 In Review
Presenter: Michael Charlton, MD, MBBS, FRCP
8:05 AM - 8:15 AM
A Tribute To Stephen A. Harrison
Presenter: Mary Rinella, MD
SESSION 1: In-depth Expert Analysis of MASH Clinical Trials – 2024
Moderators: Rohit Loomba, MD, MHSc and Mary Rinella, MD
8:15 AM - 8:30 AM
Tirzepatide Phase 2b
Presenter: Quentin Anstee, BSc (Hons), MB BS, PhD, MRCP(UK), FRCP
8:30 AM - 8:45 AM
Semaglutide Primary Analysis Phase 3
Presenter: Brent Tetri, MD
8:45 AM - 9:00 AM
REGENERATE Long Term Outcome Data
Presenter: Naga Chalasani, MD
9:00 AM - 9:15 AM
Survodutide Phase 2b
Presenter: Rohit Loomba, MD, MHSc
9:15 AM - 9:30 AM
Emerging data in FGF-21 analogs
Presenter: Mary Rinella, MD
9:30 AM - 9:45 AM
Panel Discussion
9:45 AM - 10:05 AM
Break - Exhibit Hall/Poster Viewing - For Discussions & Networking
SESSION 2: Deep Dive into Incretin and Endocrine Based Therapies
Moderators: Manal Abdelmalek, MD, MPH, FACP, FACG, FAASLD and Vlad Ratziu, MD, PhD
10:05 AM - 10:25 AM
Pleiotropic effects of FGF-21 in liver, brain and adipose tissue
Presenter: Tim Rolph, D. Phil
10:25 AM - 10:45 AM
Incretins Mono and Pluri Agonists Which Ones Make Most Sense?
Presenter: Rohit Loomba, MD, MHSc
10:45 AM - 11:05 AM
GLP1 Agonists and PAN-PPAR-Agonists; Extrahepatic Benefits and Risks
Presenter: Samuel Klein, MD
11:05 AM - 11:25 AM
Panel Discussion
11:25 AM - 11:35 AM
Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial
Presenter: Naim Alkhouri, MD
11:35 AM -11:45 AM
Liquid biopsy using whole genome methylation cell-free DNA signature for non-invasive diagnosis of at-risk MASH
Presenter: Manal Abdelmalek, MD, MPH, FACP, FACG, FAASLD
12:00 PM - 1:00 PM
CME Symposium: Comprehensive Case Challenges in MASH: Diagnosing, Staging, and Treating Patients in an Advancing Field
SESSION 3: Refining Clinical Benefit in Outcome Trials: Can CSPH Save Cirrhosis Trials?
Moderators: Meena Bansal MD and Naim Alkhouri, MD, FAASLD
4:00 PM – 4:20 PM
What Is CSPH and How Does It Change Prognosis?
Presenter: Guadalupe Garcia-Tsao, MD
4:20 PM – 4:40 PM
Non-Invasive Measurement of CSPH -Ready for Trial Time?
Presenter: Juan Abraledes, MD, FRCPC
4:40 PM – 5:00 PM
How to Exclude Cirrhosis In Candidates For MASH Therapy With Resmetirom and MASH Trials
Presenter: Mazen Noureddin, MD, MHSc
5:00 PM - 5:30 PM
Panel Discussion
5:30 PM - 5:50 PM
Break - Exhibit Hall/Poster Viewing - For Discussions & Networking
SESSION 4: The Promise of New Pharmacological Agents + Pathophysiology
Moderators: Michael Charlton, MD, MBBS, FRCP, Rohit Loomba, MD, MHSc and Vlad Ratziu, MD, PhD
5:50 PM - 6:00 PM
HSD17B13
Presenter: Nikhil Vergis, MRCP, PhD
6:00 PM - 6:10 PM
PNPLA3
Presenter: Stefano Romeo, MD, PhD
6:10 PM – 6:20 PM
FASN inhibitors
Presenter: Marie O’Farrell, PhD
6:20 PM - 6:30 PM
GM-60106: A 5HT2A Antagonist for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Presenter: Kim Hail, MD, PhD
6:30 PM - 6:45 PM
State of the art: "Differential mechanisms in early vs late hepatic fibrosis and prospects for cirrhosis reversal"
Presenter: Scott Friedman, MD
6:45 PM - 7:00 PM
Top 5 Basic Science Papers in MASH
Presenter: Meena Bansal, MD
6:45 AM - 8:00 AM
Breakfast
SESSION 5: Can Digital Pathology Save MASH Trials?
Moderators: Quentin Anstee, BSc (Hons), MB BS, PhD, MRCP(UK), FRCP and Dean Tai, PhD
8:00 AM - 8:20 AM
Recent Progress In Identifying Ballooned Cells and Resolution of Steatohepatitis With AI Assisted DP
Presenter: Quentin Anstee, BSc (Hons), MB BS, PhD, MRCP(UK), FRCP
8:20 AM - 8:40 AM
Recent Progress in Measuring Antifibrotic Effects:
Data From Clinical Trials I. (Histoindex and Clinician)
Presenters: Dean Tai, PhD and Mary Rinella, MD
8:40 AM - 9:00 AM
Recent Progress In Measuring Antifibrotic Effects:
Data From Clinical Trials II. (Pharmanest And Clinician)
Presenters: Vlad Ratziu, MD, PhD and Mathieu Petitjean, PhD
9:00 AM - 9:20 AM
AIM Explore : Assisting The Trials Vs Assisting The Clinician
Presenters: Naim Alkhouri, MD, FAASLD and Andy Beck, MD, PhD
9:20 AM - 9:40 AM
Panel Discussion: Digital Pathology In Clinical Trials How Long Before Regulatory Qualification?
Panelists: Cynthia Behling, MD, PhD, Quentin Anstee, BSc (Hons), MB BS, PhD, MRCP(UK), FRCP, Dean Tai, PhD
9:40 AM - 10:00 AM
Break - Exhibit Hall/Poster Viewing - For Discussions & Networking
SESSION 6: The Case for MetALD
Moderators: Naga P. Chalasani, MD and Becky Taub, MD
10:00 AM – 10:20 AM
Monitoring Alcohol Consumption In Clinical Trials: How And Why?
Presenter: Rohit Loomba, MD, MHSc
10:20 AM – 10:40 AM
Is MetALD An Impostor Or A Distinct Entity?
Presenter: J P Arab, MD, FRCPC
10:40 AM - 11:00 AM
The Case for MetALD Trials and How To Conduct Them
Presenter: Vijay Shah, MD
11:00 AM – 11:20 AM
Alcohol Use Disorder and How It May Interfere With MetALD Trials
Presenter: Brian Lee, MD, MAS
11:20 AM - 11:45 AM
Panel Discussion
12:15 PM - 1:15 PM
CME Symposium - Treating At-Risk MASH: What Are You Waiting For?
SESSION 7: Case Based Patient Journey
Moderators: Alina Allen, MD, MS and Vlad Ratziu, MD, PhD
4:00 PM - 4:30 PM
Case Based Patient Journey
Presenter: Mary Rinella, MD
Panelists: George Behrens, MD and Brent Tetri, MD
4:30 PM - 4:50 PM
Novel Genetics Approaches to Risk Statifications
Presenter: Stefano Romeo, MD, PhD
4:50 PM - 5:00 PM
First-in-human phase 1 study of the safety and pharmacodynamic effects of OA-235i, a PAR2 pepducin, in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (MASH)
Presenters: Athan Kuliopulos, MD, PhD
5:00 PM - 5:10 PM
Serum proteomics to unravel the role of insulin resistance in rare and common steatotic liver diseases
Presenter: Yaron Rotman, MD, MSc
5:10 PM - 5:30 PM
Break—Exhibit Hall/Poster Viewing - For Discussions & Networking
SESSION 8: Surveying the Post Approval Landscape
Moderators: Vijay Shah, MD, Michelle Long, MD, MSc, Michael Charlton, MD, MBBS, FRCP
5:30 PM - 5:50 PM
New Data on NIT Surrogates for MASH Trials
Presenter: Alina Allen, MD, MS
5:50 PM - 6:10 PM
Future of Combination Therapies
Presenter: Phil Newsome, PhD, FRCPE
6:10 PM - 6:30 PM
How Did Clinical Practice Change with Resmetirom on the Market?
Presenter: Manal Abdelmalek, MD, MPH, FACP, FACG, FAASLD
6:30 PM - 6:50 PM
Opportunities for Drug Development in the Resmetirom Era
Presenter: Vlad Ratziu, MD, PhD
6:50 PM - 7:10 PM
Panel Discussion
7:10 PM
Wrap Up
Presenter: Rohit Loomba, MD, MHSc
All Copyright © Reserved by MASH-TAG